Protocol for a prospective open-label clinical trial to investigate the utility of concurrent TBS/fNIRS for antidepressant treatment optimisation

Rebecca L D Kan,⁠¹ Arthur D P Mak,⁠² Sherry K W Chan,⁠³ Bella B B Zhang,⁣¹,⁠⁴,⁵ Kenneth N K Fong,⁠¹ Georg S Kranz,⁠¹

ABSTRACT

Introduction Repetitive transcranial magnetic stimulation (rTMS) with theta burst stimulation (i.e. TBS) of the dorsolateral prefrontal cortex (DLPFC) is an innovative treatment for major depressive disorder (MDD). However, fewer than 50% of patients show sufficient response to this treatment; markers for response prediction are urgently needed. Research shows considerable individual variability in the brain responses to rTMS. However, whether differences in individual DLPFC modulation by rTMS can be used as a predictive marker for treatment response remains to be investigated. Here, we present a research programme that will exploit the combination of functional near-infrared spectroscopy (fNIRS) with brain stimulation. Concurrent TBS/fNIRS will allow us to systematically investigate TBS-induced modulation of blood oxygenation as a proxy for induced brain activity changes. The findings from this study will (1) elucidate the immediate effects of excitatory and inhibitory TBS on prefrontal activity in TBS treatment-naive patients with MDD and (2) validate the potential utility of TBS-induced brain modulation at baseline for the prediction of antidepressant response to 4 weeks of daily TBS treatment.

Methods and analysis Open-label, parallel-group experiment consisting of two parts. In part 1, 70 patients and 37 healthy controls will be subjected to concurrent TBS/fNIRS. Intermittent TBS (iTBS) and continuous TBS (cTBS) will be applied on the left and right DLPFC, respectively. fNIRS data will be acquired before, during and several minutes after stimulation. In part 2, patients who participated in part 1 will receive a 4-week iTBS treatment of the left DLPFC, performed daily for 5 days per week. Psychometric evaluation will be performed periodically and at 1 month follow-up. Statistical analysis will include a conventional, as well as a machine learning approach.

Ethics and dissemination Ethics approval was obtained from the Institutional Review Board. Findings will be disseminated through scientific journals, conferences and university courses.

Trial registration number NCT04526002.

INTRODUCTION

Stratified medicine is still an unmet need for biological psychiatry. Despite major efforts by others and us in using neuroimaging tools to uncover diagnostic and predictive markers (e.g., Lanzenberger et al⁶), psychiatrists are still lacking such indicators with clinical utility.² The urgency for developing biomarkers for psychiatric disorders such as major depressive disorder (MDD) is demonstrated by the fact that mental disorders are the leading global burden in terms of years lived with disability.³ Moreover, mental disorders are associated with economic costs that are higher than cardiovascular disorders, cancer and diabetes combined.⁴ In light of the high percentage of treatment refractoriness, a particular need for psychiatry is to uncover markers that predict the outcome of treatments before or at an early stage after treatment starts.

Theta burst stimulation (TBS), a special form of patterned repetitive transcranial magnetic stimulation (rTMS), has finally found its way into clinical practice for the treatment of MDD. TBS is safe, effective in depressed patients that are refractory to standard pharmacological treatments, and
target selection is implemented, response
tions were observed during the 10
prefrontal activation on 1
correlating with increasing stimulation strength. Activa
tion-lasting 4–6
longer
of prefrontal excitability mediates its antidepressant effect.

Noteworthy, studies measuring cortical and cortico-
spinal activity reveal a substantial degree of individual
variability in TMS-induced modulations. For
example, Maeda et al...
modulations predict the antidepressant response after treatment.22,24

METHODS AND ANALYSIS

Study design

The study is designed as an open-label, parallel-group experiment and has two parts (see Figure 1). In part 1, patients with MDD and HC will be subjected to concurrent TBS/fNIRS. iTBS will be applied on the left DLPFC, whereas cTBS will be applied on the right DLPFC. Each participant will receive iTBS first, followed by cTBS after a delay of 1 hour to exclude possible interaction effects.24 fNIRS data acquisition will include a baseline measurement of a few minutes, will continue during the stimulation period and last for several minutes poststimulation period. The length of the poststimulation period will be optimised to cover the entire duration of anticipated facilitatory effects of iTBS.24 The TMS operator, as well as the researchers performing data analyses will be blinded regarding group membership. In part 2, patients who participated in part 1 will receive a 4-week brain stimulation treatment trial with iTBS of the left DLPFC, performed daily for 5 days per week. Patients and doctors prescribing and evaluating the treatment as well as TMS operators administering the treatment are kept blind to fNIRS results. Psychometric evaluation will be performed on the day of TBS/fNIRS measurements and at the day of treatment start, as well as after 2 and after 4 weeks of treatment. A follow-up assessment will be performed 1 month after treatment ends.

Participants

Seventy patients diagnosed with MDD in a current major depressive episode will be included. Key inclusion criteria are: MDD (DSM-5), 18≤age≤60, Hamilton depression rating scale (HAM-D-17)≥18, approval for TBS treatment by the physician in charge, stable antidepressive medication 4 weeks before treatment. Key exclusion criteria are: a history of brain surgery, head injury, stroke or neurodegenerative disorder, diagnosis of personality disorder, psychotic features, active suicidal intent, severe somatic comorbidities, cardiac pacemakers, deep brain stimulation, intracranial metallic particles, history of seizures, antiepileptics and benzodiazepines corresponding to a dose of >1mg lorazepam/day, substance dependence or abuse, if it is the primary clinical problem. For the HC group, key inclusion criteria are: age between 18 and 60, right-handedness. Key exclusion criteria are: a current or previous diagnosis of a psychiatric, neurological disorder or severe internal illness, common contraindications to rTMS,25 and a psychiatric disorder in their first-degree relatives.

The sample size was determined based on previous studies demonstrating that motor cortex excitability modulation significantly predicts antidepressant response of a 2 week rTMS treatment.10 A minimum sample size of 37 was determined using an effect size of r=0.43,10 a power of 0.8 and an alpha of 0.05 using G*Power V.3.0.10 (Point biseral correlation model, two-tailed). Given an expected dropout rate of 15%, conservative sample size was set to 43 participants. However, in order to ensure adequate power and the ability to have reliable estimates and replicable findings, we aim to include a sample size of 70 or above. In addition, we will recruit 47 HC to participate in the TBS/fNIRS measurement. The sample size was based on the comparison of MEP facilitation obtained in MDD (8±49%)10 and HC (37.9±53.6%),15 determined using an effect size of d=0.58, a power of 0.8 and an alpha of 0.05 using G*Power V.3.0.10 (unpaired two sample t-test, two-tailed). Four sites will be involved in patient recruitment: (1) the Department of Psychiatry, Chinese University of Hong Kong and its associated hospital, the Prince of Wales Hospital (Dr Arthur Mak, Co-I); (2) the OT outpatient clinic at the Department of Rehabilitation Sciences, The Hong Kong Polytechnic University (Dr Kenneth Fong, Co-I); (3) the Department of Psychiatry, Kowloon hospital (Dr Wai Chung Yan, Dr Athena K Y Chan) and (4) the Department of Psychiatry, The University of Hong Kong and its associated hospital, the Queen Mary Hospital (Dr Sherry K W Chan, Co-I). HC participants will be recruited via posters and leaflets displayed at billboards on the university campus and community centres, community websites and social media. Participants will be screened by an experienced psychiatrist and the study including all study-related procedures will be explained to participants in oral and written form prior inclusion. The study will be performed in accordance with the Declaration of Helsinki,26 including current revisions. All participants will be asked for written informed consent prior to inclusion in the study. Participants can decide to withdraw from the study at any time. The investigator may remove participants from the trial if exclusion
criteria have been met or ending the participation is in the interest of the participant or study.

**Theta-burst stimulation**

TBS comprises 3-pulse 50 Hz bursts, applied every 200 ms (at 5 Hz) as described previously. iTBS consists of 2 s trains with an inter-train-interval of 8 s. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses. cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses. Concurrent TBS/fNIRS stimulation will be applied over the left (iTBS) and right (cTBS) DLPFC at an intensity of 90% resting motor threshold (RMT), this corresponds to ~110% of the active motor threshold, an intensity that also elicited robust DLPFC activation in a recent concurrent TMS/MRI study. Stimulation at 90% RMT will also ensure compliance, reduce sensory discomfort and minimise dropout rates during the concurrent TBS/fNIRS experiment. Still, scalp discomfort will be recorded directly after the stimulation. We refrained from choosing an intensity of 120% RMT (which will be applied during antidepressant treatment) for the concurrent TBS/fNIRS experiment because such intensity would unlikely be tolerated by all patients as they are stimulation-naive at the time of the experiment. The stimulation site over the DLPFC will be determined using the international 10–20 system and corresponds to the F3 label, determined using the optimised method by Beam et al. TBS of the PFC is generally well tolerated, even at higher stimulation intensities. Antidepressant treatment comprises daily sessions of iTBS of the left DLPFC, five times a week for 4 weeks. Stimulation intensity will be 120% RMT (titration to full therapeutic dose over the first 3 days), as approved by the Food and Drug Administration in the USA. The stimulation site will be the same as in the concurrent TBS/fNIRS stimulation. Treatment will be performed at the TMS treatment centres of the participating local clinics (Department of Psychiatry, The University of Hong Kong and The Chinese University of Hong Kong and at the Department of Rehabilitation Sciences, The Hong Kong Polytechnic University).

**Functional near-infrared spectroscopy**

We will make use of the fNIRS system Imagent from ISS, Champaign, Illinois, USA (http://www.iss.com/biomedical/instruments/imagent.html) to determine changes in haemoglobin concentrations before, during and after TBS. Imagent uses a sensor that is embedded in a rectangular rubber pad with prisms inside so that optical fibres are rested tangentially instead of perpendicularly on the head surface. This arrangement allows the placement of the sensor directly underneath the TMS coil in close proximity to the stimulation site. Concurrent TBS/fNIRS poses technical and conceptual challenges. Although NIRS has the advantage of being relatively insensitive to motion artefacts, pilot data from our lab show significant stimulation-related artefacts if sensors and the TMS coil touch each other. Hence, a minimum distance of a few millimetres between probes and the TMS coil will be ensured before the start of measurements. The lowest fNIRS probes will match the Fp1-Fp2 line in order to cover most of the PFC extending to the temporal lobes (DLPFC, ventrolateral, frontopolar and superior temporal regions). The device measures changes in HbO, deoxy-haemoglobin (HbR) and total haemoglobin (HbT) using two wavelengths of infrared light (695 and 830 nm). With a source-detector spacing of 3 cm, changes in Hb can be measured at a depth of 2–3 cm corresponding to the cerebral cortex. fNIRS is not a perfect measure of brain activity and there are several sources of artefacts that need to be carefully considered. We will primarily focus on HbO since it may closer reflect BOLD changes as measured by fMRI. The primary imaging endpoint will be the mean HbO amplitude of left and right DLPFC during and after the TBS stimulation. Secondary endpoints include mean Hb amplitudes during and after iTBS and cTBS, the steepness in the decline of Hb and ascent of HbO values, as well as the area under curve of HbO and Hb values during stimulation. During concurrent TBS/fNIRS, participants will comfortably sit in a chair. Participants will be carefully instructed about the nature of the experiment prior to the TBS/fNIRS run.

**Psychiatric assessment**

HAMD17 is a standard instrument used in most clinical trials to screen for MDD. We will use a baseline score of HAMD17 ≥ 18 to apply a generally accepted definition of depression severity as inclusion criteria and to ensure comparability with other clinical trials. However, we will use the Montgomery-Asberg depression rating scale (MADRS) as the primary outcome measure because this symptom rating scale is more sensitive to changes over time. In addition, we will also use the Patient Health Questionnaire 9 (PHQ-9) as self-report questionnaire to assess subjective treatment effects over time. The PHQ-9 is widely used in psychiatric research. Therefore, we use different instruments for inclusion criteria and measurement of treatment response including both rater assessment and self-report inventories, a common practice in many clinical trials. All psychometric scales used in this study are available in Chinese, and show comparable psychometric qualities compared with the original scales. For example, the inter-rater reliability of the Chinese version of HAMD was r=0.94, as was the sensitivity (0.79) and specificity (0.80). The Chinese version of MADRS and Quick inventory of depressive symptomatology-clinician rating (QIDS-C) shows a high correlation with the HAMD (0.853 and 0.75, respectively). The Chinese version of all scales have been used in several previous clinical trials which involved Hong Kong populations.

Psychiatric assessment includes a range of clinical scales, administered at baseline on the day of the TBS/fNIRS measurement, after 2 and 4 weeks of treatment, as well as at follow-up 1 month after treatment ends. The primary clinical outcome measure will be the response rate after...
treatment (defined by a Chinese-MADRS (C-MADRS) score reduction ≥50% of baseline). Secondary endpoints will be the remission rate after treatment (defined by a C-MADRS ≤7), cut-off scores for the C-MADRS are based on Liu et al.33 Further, secondary endpoints include the absolute reduction of mean Chinese-HAMD17 (C-HAMD17) and Chinese-IDS-C (C-IDS-C) after 2 and 4 weeks of treatment and at 1-month follow-up, as well as the response (C-IDS-C and C-HAMD17 ≥50% of baseline) and remission rates (C-IDS-C≤12, C-HAMD17 ≤7) of patients after 4 weeks of treatment,37 38 a reduction of 50% on a depression symptom rating scale is the most common response criterium in depression trials. Adverse events (AE) will be assessed according to good clinical practice (GCP) using an AE-questionnaire to detect unwanted side effects related to the treatment. Suicide will be evaluated on each treatment day. Similarly, depression severity will be evaluated at each treatment day using the Chinese version of the PHQ-9 (C-PHQ9). Patients will be discontinued if they experience worsening in depression, defined as an increase in C-PHQ9 from baseline of more than 25% during two consecutive assessments, or development of active suicidal intent or attempted suicide. Potentially occurring serious AEs will be recorded.

Data processing and statistical analysis

fNIRS data analysis will follow the standard processing steps. This includes spatial registration (recording of standard cranial landmarks nasion, inion, left and right ear and the 3D locations of the fNIRS probes); transformation to MNI space; band-pass filtering for motion artefact removal; and estimation of the haemodynamic response function using GLM, as implemented in the NIRS Toolbox for MATLAB. Comparisons between HbO values at baseline and during/after stimulation will reveal TBS-related de/activations. A t-test between prestimulation and poststimulation will be performed to test hypothesis 1. Hypothesis 1 will be supported if there is a significant increase and decrease in prefrontal HbO after iTBS and cTBS, respectively. A t-test between prestimulation and during stimulation will be performed to test hypothesis 2. Hypothesis 2 will be supported if there is a significant change in prefrontal HbO during stimulation. An F-test for the comparison of the variance in HbO values before vs after stimulation will be performed to test hypothesis 3. Hypothesis 3 will be supported if the F-test is significant. Similarly, an F-test for the comparison of the variance in HbO values in MDD vs HC will be performed to test hypothesis 4. Hypothesis 4 will be supported if the F-test is significant. Analyses will be performed using the IBM SPSS software (http://www-01.ibm.com/software/analytics/spss/). The alpha level will be set at 0.05, adjusted for multiple comparisons using the Bonferroni-Holm procedure. For hypothesis 3, we will pursue two predictive modelling approaches, a conventional statistical analysis approach, as well as a machine learning approach.39 First, a logistic regression analysis will be performed to define significant predictors of treatment response (defined as MADRS reduction ≥50% of baseline, see above). Logistic regression will be calculated as implemented in the generalised linear model function ‘glm’ of the statistical software ‘R’ (https://www.r-project.org/). Predictors will include imaging endpoints as given above, as well as sociodemographic and psychosocial variables (including the classification of patients as pharmacologically treatment resistant, TRD, defined by a failed treatment response after two or more consecutive antidepressants of adequate duration and dosage). Hierarchical multiple linear regression models will also be calculated to determine the relationship between MADRS reductions and secondary imaging endpoints as potential response predictors. Second, we will use machine learning algorithms for the classification of patients. We will test different algorithms since there is no established rule for the choice of an optimal machine learning approach. We will start with a dichotomous classification using the Random Forest (RF) package for R (ran. r-project.org/) and determine the most useful predictors for distinguishing responders from non-responders. RF is an ensemble tree classification tool that randomly selects subsamples of observations and builds a decision tree for the optimal splitting of these observations according to an outcome variable by a combination of predictors. For each split, the best performing predictor out of a random selection is applied. RF has the advantage of being straightforward and less susceptible to overfitting compared with other machine learning classifiers. To measure the predictive power of our classification model, we will use a fivefold cross-validation design. This allows for optimal validation in the absence of an independent test set.40 There is no established method of power calculation for RF. However, we will restrict HbO measurements to few prefrontal channels in order to keep the number of features for classification below the number of observations, thereby preventing the problem of hyper-dimensionality. Receiver operating characteristics will be plotted using the ROCR package for the R-software.

Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Ethics and dissemination

Ethics approval was obtained from the Institutional Review Board of the Hong Kong Polytechnic University (reference numbers HSEARS20200120005, CRESC202009), as well as from the Institutional Review Boards of participating hospitals. An information sheet will be provided to participants before the experiment and a consent form will be signed by both PI and participant to protect the right of both parties. Participants will receive reimbursement for their participation. The data will be stored in an encrypted way and the accessibility is restricted to the
researcher team. The study will start in January 2022 and is expected to be completed in December 2023.

The findings of this study will be disseminated through scientific journals, academic conferences, and university courses.

**Challenges and potential limitations of this study**

Although fNIRS has the advantage of being relatively insensitive to motion artefacts, we expect stimulation-related artefacts caused by muscle contractions on the scalp given that sensors are in close proximity to the TMS coil. Furthermore, stimulation may have direct effects on superficial microvasculature. A challenge of this study will therefore be to minimise such artefacts. A variety of techniques have been proposed to resolve these and other issues related to TMS-fNIRS integration. Moreover, using fNIRS in this study will limit the interpretation of our results due to the inherent limitations of the technique of fNIRS. This includes a restriction to measurements of shallow cortical regions (compared with fMRI) and restrictions in temporal resolution (as compared with EEG). Finally, the NIRS probe proposed to be used in our study only covers a small cortical area underneath the coil, which limits the analysis of stimulation effects to a small region of interest.

**Author affiliations**

1 Department of Psychiatry and Psychotherapy, Medical University of Vienna, Wien, Austria
2 Department of Psychiatry, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
3 Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China
4 Department of Psychiatry and Psychotherapy, Medical University of Vienna, Wien, Austria
5 The State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong, People’s Republic of China

**Twitter** Arthur D P Mak @ArthurDPMak

**Contributors** GSK conceived the study and analysis. GSK and RLKD drafted the protocol and will conduct the data analysis. RLKD, BBBBB and KNKF will collect the data. ADPM and SKWC will assist in recruiting participants and performing the stimulation treatment. All the authors reviewed the protocol and agree to the final version being submitted.

**Funding** This work is supported by the General Research Fund (GRF) under the University Grants Committee (UGC) of the Hong Kong Special Administrative Region, grant number 15100120.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

Arthur D P Mak http://orcid.org/0000-0003-1627-6434
Bella B Zhang http://orcid.org/0000-0003-2580-3371
Georg S Kranz http://orcid.org/0000-0002-3892-1804

**REFERENCES**

22. Branchi I. The double edged sword of neural plasticity: increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover. *Psychoneuroendocrinology* 2011;36:339–51.